 |
Parkinsons News: 273 headlines |
|
|||||
Celebrity Fight Night Video  |
||||||||
|
||||||||
|
||||||||
| Sources used by our Parkinsons News Channel Research Team: | ||||||||
| The New York Times, CNN, FOX, CBS, BBC, Mayo Clinic, Johns Hopkins Medicine, UCLA Medical Center, National Institute of Health, Stanford Hospital, Memorial Sloan- Kettering, Yale Cancer Center, Massachusetts General Hospital, Brigham and Women's Hospital, University of Michigan, M. D. Anderson Cancer Center, National Institute of Health, American Cancer Association, NBC, Reuters News, American College of Cardiology, Journal of the American Medical Association & 100's more | ||||||||
| Links | ||||||||
| Barrow Neurological Institute | ||||||||
| Archives |
Thursday
Serono: Parkinsons drug deal will fit with Merck merger
Serono has in-licensed phase III Parkinson's drug safinamide in a deal with Newron Pharmaceuticals.
The addition of safinamide to Serono's late stage R&D pipeline will fill the gap left by Merck KGaA's halted Parkinson's disease (PD) product, sarizotan, when the two companies merge to form Merck-Serono Biopharmaceuticals. However, the drug is not expected to have a large impact on the PD market and thus will not be a key growth driver for the company.
'Content Serono has competed a licensing deal with Newron Pharmaceuticals regarding PD drug, safinamide. The deal involves an undisclosed upfront payment as well as milestone and royalty payments worth up to $200 million. Serono will resume all further development costs while Newron will maintain the option to co-promote the drug in Spain and Italy. An incremental milestone and royalty agreement will see both parties rewarded from the success of safinamide.
Safinamide, with its multiple action has shown promise in phase III trials in treating early stage PD when used in combination with an oral dopamine agonist. However, the market outlook is limited and safinamide would only reach blockbuster status if it can show significant advantages over current treatments and broaden its indications into Alzheimer's disease and Restless Leg syndrome.
Serono has in-licensed phase III Parkinson's drug safinamide in a deal with Newron Pharmaceuticals.
The addition of safinamide to Serono's late stage R&D pipeline will fill the gap left by Merck KGaA's halted Parkinson's disease (PD) product, sarizotan, when the two companies merge to form Merck-Serono Biopharmaceuticals. However, the drug is not expected to have a large impact on the PD market and thus will not be a key growth driver for the company.
'Content Serono has competed a licensing deal with Newron Pharmaceuticals regarding PD drug, safinamide. The deal involves an undisclosed upfront payment as well as milestone and royalty payments worth up to $200 million. Serono will resume all further development costs while Newron will maintain the option to co-promote the drug in Spain and Italy. An incremental milestone and royalty agreement will see both parties rewarded from the success of safinamide.
Safinamide, with its multiple action has shown promise in phase III trials in treating early stage PD when used in combination with an oral dopamine agonist. However, the market outlook is limited and safinamide would only reach blockbuster status if it can show significant advantages over current treatments and broaden its indications into Alzheimer's disease and Restless Leg syndrome.